Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with atypical agent (low certainty).
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with atypical agent (low certainty).
Selective serotonin reuptake inhibitor (SSRI) showed no clear difference in study dropouts at 6‐12 weeks compared with atypical agent (low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
Selective serotonin reuptake inhibitor antidepressant showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants experiencing adverse effects compared with placebo (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes completion of scheduled treatment compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether summary of findings table ‐ Arginine and micronutrients changes acceptability of nutritional supplements: non‐adherence compared with standard diet (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.